Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 8
2005 7
2006 2
2007 7
2008 8
2009 9
2010 12
2011 19
2012 19
2013 28
2014 26
2015 25
2016 21
2017 21
2018 30
2019 26
2020 32
2021 35
2022 31
2023 40
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
First-in-human stage III/IV melanoma​ clinical trial of immune priming agent IFx-Hu2.0.
Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Delhawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. Markowitz J, et al. Among authors: kim y. Mol Cancer Ther. 2024 Apr 24. doi: 10.1158/1535-7163.MCT-23-0652. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38657233
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma.
Naghavi AO, Bryant JM, Kim Y, Weygand J, Redler G, Sim AJ, Miller J, Coucoules K, Michael LT, Gloria WE, Yang G, Rosenberg SA, Ahmed K, Bui MM, Henderson-Jackson EB, Lee A, Lee CD, Gonzalez RJ, Feygelman V, Eschrich SA, Scott JG, Torres-Roca J, Latifi K, Parikh N, Costello J. Naghavi AO, et al. Among authors: kim y. BMC Cancer. 2024 Apr 9;24(1):437. doi: 10.1186/s12885-024-12151-7. BMC Cancer. 2024. PMID: 38594603 Free PMC article. Clinical Trial.
Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma.
Peak T, Tian Y, Patel A, Shaw T, Obermayer A, Laborde J, Kim Y, Johnson J, Stewart P, Fang B, Teer JK, Koomen J, Berglund A, Marchion D, Francis N, Echevarria PR, Dhillon J, Clark N, Chang A, Sexton W, Zemp L, Chahoud J, Wang L, Manley B. Peak T, et al. Among authors: kim y. Lab Invest. 2024 Feb 29;104(5):102041. doi: 10.1016/j.labinv.2024.102041. Online ahead of print. Lab Invest. 2024. PMID: 38431116
381 results